GSK_Annual_Report_2021

Our continual investments in business, augmenting people capabilities and delivering unmatched healthcare solutions enables us to achieve industry-leading performance and continued success. in vaccines self- pay market #1 in terms of volume in IPM #5 among MNCs in pharmaceuticals (by value) #2 in dermatology therapy area #1 24% Revenue from vaccines 76% Revenue from pharmaceuticals 3.1 units/sec Annual units sale of Betnovate-N 1.7 Rx/sec Annual prescription reflection of Calpol (Solid + Liquid) 5 GSK products feature in the top 60 Indian Pharmaceutical Market (IPM) brands Amoxycillin + Clavulanic acid Our priorities for the next year will not only allow us to build business momentum, but our learnings and adoption of best practices from a pandemic year will provide the required competitive leverage. Source: IMS MAT March 2021 13 Annual Report 2020-21